Fig. 4
hlMSC-CM shows higher efficacy than twice the IC50 of cisplatin in inhibiting the growth of tumor spheres in H28 cells. H28 cells were treated in the absence or presence hlMSC-CM (a), 1× IC50 cisplatin (b) and 2× IC50 cisplatin (c) at the indicated periods after which sphere-formation assays were performed. Results indicate the sphere efficiencies of the hlMSC-CM-and cisplatin-treated cells relative to the nontreated controls. d-f Representative images of the hlMSC-CM-, cisplatin-treated cells and nontreated cells as indicated. Data represent the means and ± standard deviations of three independent experiments each. *p < 0.05, ***p < 0.001, ****p < 0.0001. h Hours, hlMSC-CM Human lung-derived mesenchymal stem cell-conditioned media, IC 50 Half maximal inhibitory concentration